Evidence map›Paper›PMID 34300575›Full record

ArticleSensors (Basel, Switzerland)2021

A Dual-Sensor-Based Screening System for In Vitro Selection of TDP1 Inhibitors.

Ann-Katrine Jakobsen, Josephine Geertsen Keller, María Gonzalez, Endika Martin-Encinas, Francisco Palacios, Concepcion Alonso, Birgitta Ruth Knudsen, Magnus Stougaard

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ann-Katrine JakobsenDepartment of Pathology, Aarhus University Hospital, N 8200 Aarhus, Denmark.
Josephine Geertsen KellerDepartment of Clinical Medicine, Aarhus University, N 8200 Aarhus, Denmark.ORCID 0000-0003-0567-3653
María GonzalezDepartment of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain.
Endika Martin-EncinasDepartment of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain.
Francisco PalaciosDepartment of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0001-6365-0324
Concepcion AlonsoDepartment of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain.ORCID 0000-0003-0866-3493
Birgitta Ruth KnudsenDepartment of Molecular Biology and Genetics, Aarhus University, C 8000 Aarhus, Denmark.
Magnus StougaardDepartment of Pathology, Aarhus University Hospital, N 8200 Aarhus, Denmark.
Aarhus University · DKUniversity of the Basque Country · ES

Funding

Agencia Estatal de Investigación (AEI) y Fondo Europeo de Desarrollo Regional FEDER; RTI2018-101818-B-I00, UEAgnes og Poul Friis Fond 81008-003Gobierno Vasco, Universidad del País Vasco GV, IT 992-16; UPVKøbmand Sven Hansen og Hustru Ina Hansens Fond 08072018Ministerio de Ciencia, Innovación y Universidades
6 · The paper itself

Abstract

DNA sensors can be used as robust tools for high-throughput drug screening of small molecules with the potential to inhibit specific enzymes. As enzymes work in complex biological pathways, it is important to screen for both desired and undesired inhibitory effects. We here report a screening system utilizing specific sensors for tyrosyl-DNA phosphodiesterase 1 (TDP1) and topoisomerase 1 (TOP1) activity to screen in vitro for drugs inhibiting TDP1 without affecting TOP1. As the main function of TDP1 is repair of TOP1 cleavage-induced DNA damage, inhibition of TOP1 cleavage could thus reduce the biological effect of the TDP1 drugs. We identified three new drug candidates of the 1,5-naphthyridine and 1,2,3,4-tetrahydroquinolinylphosphine sulfide families. All three TDP1 inhibitors had no effect on TOP1 activity and acted synergistically with the TOP1 poison SN-38 to increase the amount of TOP1 cleavage-induced DNA damage. Further, they promoted cell death even with low dose SN-38, thereby establishing two new classes of TDP1 inhibitors with clinical potential. Thus, we here report a dual-sensor screening approach for in vitro selection of TDP1 drugs and three new TDP1 drug candidates that act synergistically with TOP1 poisons.

Indexed as

DNA Topoisomerases, Type IPhosphoric Diester HydrolasesDNADNA DamageHigh-Throughput Screening AssaysHumansPhosphodiesterase InhibitorsDNADNA Topoisomerases, Type IPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesTDP1 protein, humanbiosensorcancerDNA sensordrug screeninginhibitortopoisomerase 1tyrosyl-DNA phosphodiesterase 1

Identifiers

PMID34300575
PMCPMC8309759
OpenAlexW3181454573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.